Apollomics announces efficacy of vebreltinib in nsclc patients with metex14 skipping mutation achieving an overall response rate (orr) of 75%

Foster city, calif., oct. 23, 2023 (globe newswire) -- apollomics inc. (nasdaq: aplm) (the “company”), today announced the presentation of vebreltinib efficacy and safety data from the kunpeng clinical trial at the european society of medical oncology congress (esmo) 2023, being held in madrid, spain from october 20-24, 2023.
APLM Ratings Summary
APLM Quant Ranking